Endoscopes Market: as AI-powered computer-aided detection integration with flexible GI endoscopy platforms improves colorectal adenoma detection rates and drives EVIS X1 platform adoption that generated a 44% increase in North America GI endoscopy system sales in Q2 FY2025, so Olympus's approximately 70% GI endoscope market share concentration creates both a durable commercial position and GPO pricing leverage dynamics that compress per-unit ASPs at group purchasing accounts, and so Ambu A/S single-use endoscope 15.4% organic growth alongside the June 2025 aScope 5 Cysto HD PCNL FDA clearance creates a new revenue category growing alongside the reusable GI endoscope base rather than fully substituting it at the total market level.

The global endoscopes market size was USD 10.86 Billion in 2025 and is expected to register a revenue CAGR of 7.5% during the forecast period. Market revenue growth is supported by factors such as accelerating adoption of AI-powered computer-aided detection systems integrated with flexible GI endoscopy platforms that improve colorectal adenoma detection rates and create a technology upgrade cycle at gastrointestinal endoscopy centres, the expanding application of endoscopy across therapeutic interventional procedures including endoscopic submucosal dissection and endoscopic ultrasound-guided interventions that require advanced multi-channel flexible platforms, as well as the single-use disposable endoscope category growing at 15.4% organic rate alongside the reusable platform base. The first driving factor is the AI-CAD integration with flexible GI endoscopy platforms creating a technology upgrade cycle. The American Cancer Society reported in its 2024 Colorectal Cancer Facts and Figures that colorectal cancer remains the second leading cause of cancer death in the United States with approximately 153,000 new cases and 53,000 deaths annually, with colonoscopy screening recommended by USPSTF for all adults aged 45 to 75, establishing a mandatory population-scale endoscopy screening programme that represents the largest procedural demand driver for flexible GI endoscope procurement. The American College of Gastroenterology reported in its 2024 clinical practice statistics update that GI endoscopy procedure volumes in the United States exceeded 19 million procedures annually, with colonoscopy accounting for approximately 15 million procedures. The second driving factor is the commercial expansion of Olympus EVIS X1 with AI-CAD integration generating a 44% increase in North America GI endoscopy system sales in Q2 FY2025, demonstrating that AI-integrated platform upgrade cycles drive capital equipment replacement above the underlying procedure volume growth rate. The third driving factor is Karl Storz's acquisition of Surgical Inc. in August 2024 and ANKLIN in January 2025, expanding its North American surgical endoscopy presence and transitioning from distributor to direct commercial sales infrastructure in key markets. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way Olympus's January 2024 acquisition of Taewoong Medical for approximately USD 370 million compounds the per-procedure revenue generated from Olympus's GI endoscope installed base by adding biliary and enteric stenting devices consumed at every ERCP and EUS-guided intervention procedure, deepening the therapeutic accessories revenue stream attached to the Olympus GI endoscope commercial relationship at hospital procurement level. Once a hospital GI department has standardised on Olympus EVIS X1 colonoscopes, gastroscopes, and duodenoscopes as its primary endoscopy platform and established Olympus as the preferred therapeutic accessories supplier through the Endo Therapy product range, adding Taewoong biliary stenting and enteric stenting devices to the Olympus accessory portfolio means that Olympus can offer the complete GI endoscopy procedure package from scope to accessory through a single commercial relationship, reducing the accessory procurement decisions that would otherwise go to Cook Medical, Boston Scientific, or standalone stenting device suppliers. As a result, the per-procedure Olympus revenue at each GI endoscopy account compounds as the Endo Therapy accessory menu expands, and the forecast tilts toward Olympus sustaining above-market revenue growth at its existing installed base through accessory portfolio depth rather than solely through new endoscope platform placements. For instance, in May 2025, Olympus received FDA 510(k) clearance for its EZ1500 series endoscopes incorporating Extended Depth of Field technology, enabling endoscopists to maintain sharp focus across a broader depth range from close mucosal inspection to distant lumen viewing without manual focus adjustment, one of several technology refresh clearances that sustain EVIS platform upgrade cycles at Olympus's installed base accounts. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the AI-CAD integration with GI endoscopy platforms that creates a clinical quality upgrade rationale for endoscopy programme directors to replace functional legacy endoscopy systems with AI-integrated platforms before the end of the legacy system's service life, accelerating the capital replacement cycle above what procedure volume growth alone would sustain. Computer-aided detection systems integrated within flexible GI endoscopy platforms analyse real-time endoscopic video feeds using deep learning algorithms trained on millions of annotated endoscopic images to identify polyps, adenomas, early gastric lesions, and Barrett's oesophagus segments, with Olympus reporting in commercial communications for EVIS X1 that the AI-powered system demonstrated 25% improvement in lesion detection and diagnostic accuracy. The Endoscopic Solutions Division reported 10% year-on-year revenue growth in Q2 FY2025 with North America seeing a 44% increase in GI endoscopy system sales, driven in part by EVIS X1 platform commercial adoption at US hospital and ambulatory surgery centre GI departments implementing the AI-CAD clinical quality upgrade. The ESGE published its updated 2024 guidelines on quality indicators for colonoscopy, establishing adenoma detection rate benchmarks that drive endoscopy programme quality improvement investment including AI-assisted detection software and high-definition imaging platforms that improve ADR metrics across European national colorectal cancer screening programmes. Fujifilm's ELUXEO 7000 incorporates Bio-spectral Endoscopy optical technology competing with Olympus EVIS X1's narrowband and texture enhancement imaging modes, and Karl Storz announced in April 2024 a partnership with a leading AI company to develop advanced diagnostic solutions integrating AI image analysis with Karl Storz's endoscope platforms. The effect on the market is an accelerated capital replacement cycle at GI endoscopy programmes adopting AI-integrated platforms, generating higher per-system revenue at above-list pricing for AI software licences and at premium hardware ASPs for AI-integrated endoscope cameras. These are some of the key factors driving revenue growth of the market.

The second driver is the single-use disposable endoscope category establishing itself as a net additive revenue stream to the total endoscope market rather than purely substituting reusable scope revenue, because single-use endoscopes command higher per-procedure ASPs than the annualised equivalent of reusable scope depreciation per procedure at typical replacement cycle lengths, generating higher annual category revenue per procedure than the per-procedure share of a reusable scope's purchase price amortised across its service life. Ambu A/S reported in its FY2024/25 Annual Report that its Endoscopy Solutions segment revenue grew 15.4% organically with the Urology, ENT, and GI business group growing 19.6% organically, and the June 2025 FDA clearance of the aScope 5 Cysto HD as the first single-use flexible cysto-nephroscope for PCNL marked the expansion of single-use endoscopy into complex kidney stone procedure applications where reusable nephroscopes had been the only option. Olympus received FDA 510(k) clearance in May 2025 for its EZ1500 series endoscopes incorporating Extended Depth of Field technology, maintaining technology platform currency in the reusable GI endoscope segment where Olympus's 70% market share creates an incumbent advantage for technology upgrade cycles at existing Olympus installed base accounts. In January 2024, Olympus acquired Taewoong Medical for approximately USD 370 million, strengthening Olympus's GI Endo Therapy accessory portfolio with biliary and enteric stenting that competes directly with Cook Medical, Boston Scientific, and other therapeutic accessory suppliers across the hospital GI endoscopy procedure accessory spend category. The effect on the market is a dual-track revenue expansion where reusable GI endoscope platform upgrades to AI-integrated systems generate capital replacement revenue above the underlying procedure volume growth rate and single-use endoscope category expansion at 15%+ organic growth adds an incremental revenue stream. These are some of the key factors driving revenue growth of the market.

Olympus Corporation's Endoscopic Solutions Division reported 10% year-on-year revenue growth in Q2 FY2025 with North America generating a 44% increase in GI endoscopy system sales, driven by EVIS X1 platform commercial adoption integrating 4K imaging and AI-powered computer-aided detection. At approximately 70% GI endoscope market share globally, Olympus's EVIS X1 adoption cycle is the largest single driver of endoscope capital equipment market revenue growth across the 2025 to 2028 period.

The third driver is the geographic and commercial infrastructure expansion of the surgical and specialty rigid endoscope segment through Karl Storz's direct sales transition and the NHS GBP 4.1 billion endoscopy programme creating a large-scale new endoscope procurement cycle at UK hospitals. Karl Storz acquired Surgical Inc., United States, in August 2024 to expand advanced surgical and endoscopic product offerings in the North American surgical endoscopy market, moving from distributor-based commercial relationships in some surgical specialties to direct hospital and surgeon account management with the clinical selling capability that Karl Storz's premium pricing and surgeon specification advantage requires. Karl Storz followed with the January 2025 acquisition of ANKLIN, its long-standing Swiss distributor, to strengthen direct sales in Switzerland and transition from indirect distributor to direct customer engagement across the full Karl Storz product portfolio in the Swiss market, consistent with a pattern of distributor acquisition in markets where technical complexity and customer relationship depth justify higher-cost direct commercial infrastructure. The NHS GBP 4.1 billion endoscopy infrastructure programme is commissioning new endoscopy rooms at NHS trusts across England, each requiring fresh endoscope inventory, creating a large-scale procurement cycle for Olympus, Fujifilm, and Karl Storz in the UK market where Olympus's incumbent NHS installed base relationships compete with Fujifilm's ELUXEO AI integration value proposition at trusts establishing entirely new endoscopy departments without incumbent scope loyalty. The effect on the market is combined revenue growth from Karl Storz's direct sales penetration in North American and Swiss surgical endoscopy accounts and NHS programme-driven GI endoscope procurement at UK NHS trusts that supplements the organic commercial growth from AI-integrated platform upgrade cycles. These are some of the key factors driving revenue growth of the market.

However, the endoscopes market faces adoption constraints from single-use disposable penetration reducing reusable endoscope replacement cycles at converting departments, Olympus GPO pricing leverage dynamics compressing per-unit ASPs, and EU MDR compliance cost adding timeline to European new model introductions. Because Ambu A/S, Boston Scientific, Olympus, and Karl Storz are competing to establish single-use formats in bronchoscopy and ureteroscopy that reduce the number of reusable flexible endoscopes in hospital inventory, each department converting to single-use extends the replacement cycle for reusable scopes at that facility by reducing the per-scope procedure volume that drives premature scope wear, reducing annual reusable endoscope procurement volume at converting departments. Olympus's approximately 70% GI endoscope market share creates pricing and margin pressure at commercial accounts where hospital group purchasing organisations use Olympus's dominant position as a procurement leverage point to negotiate per-unit price discounts that compress Olympus's per-system ASP even as clinical adoption volumes grow. EU MDR full implementation requirements effective 2024 for endoscopic devices impose clinical evidence and post-market surveillance obligations that add regulatory compliance cost and timeline to new endoscope model commercial introductions, reducing the speed of technology platform refresh cycles and increasing per-model regulatory investment before European market access. These factors substantially limit endoscopes market growth over the forecast period.

Based on end-use, the global endoscopes market is segmented into hospitals, ambulatory surgical centres, and specialty clinics and outpatient endoscopy centres. Hospitals hold the largest revenue share, driven by the concentration of complex therapeutic endoscopy including ERCP, EUS-guided interventions, endoscopic submucosal dissection, and peroral endoscopic myotomy at hospital-based gastroenterology and surgical departments that require the broadest endoscope type inventory including therapeutic-channel colonoscopes, side-viewing duodenoscopes, linear-array echoendoscopes, and multi-bending therapeutic gastroscopes. Olympus's EVIS X1 44% North America GI system sales increase in Q2 FY2025 was concentrated at hospital accounts upgrading to AI-integrated endoscopy systems, confirming hospital endoscopy programmes as the primary driver of GI endoscope capital equipment replacement revenue.

Based on regional analysis, the endoscopes market in North America accounted for largest revenue share in 2025. The United States leads through the highest per-capita colonoscopy procedure rate globally with CMS recommending colorectal cancer screening beginning at age 45, the largest concentration of GI ambulatory surgery centres, and the commercial headquarters of Boston Scientific's EXALT single-use endoscope platform and Ambu A/S's US distribution. Olympus Endoscopic Solutions Division reported that North America accounted for 38% of total Olympus revenue and saw a 44% increase in GI endoscopy system sales in Q2 FY2025, confirming the US as Olympus's largest single-country endoscope revenue market. Stryker's endoscopy division contributes rigid endoscope revenue from laparoscopy, arthroscopy, and ENT endoscopy at US hospital and ASC accounts.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, South Korea, and Australia represent the four largest national endoscope markets. Japan represents Olympus's domestic market where the company maintains the highest market share concentration in GI endoscopy, with Japanese GI endoscopy society guidelines supporting annual upper GI screening examinations that generate the highest per-capita upper GI endoscopy procedure rate globally. China's expanding colorectal cancer screening programme covering urban populations at municipal hospitals and the NHC cancer early detection initiative create growing procedure volume demand for flexible GI endoscopes at tier-2 and tier-3 Chinese hospitals upgrading endoscopy departments, leaving more room for Asia Pacific market growth than in North America where AI-integrated platform adoption is already well advanced.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, France, and Scandinavia represent the four largest national endoscope markets. Karl Storz SE & Co. KG, headquartered in Tuttlingen Germany, operates across more than 50 countries with strong commercial positions in rigid endoscopy for urology, ENT, and laparoscopy, and acquired ANKLIN its long-standing Swiss distributor in January 2025 to strengthen direct sales in Switzerland. The NHS GBP 4.1 billion endoscopy infrastructure programme is driving GI endoscope procurement for new and expanded NHS endoscopy units, creating a large-scale procurement cycle that represents a strategically significant revenue opportunity for Olympus, Fujifilm, and Karl Storz in the UK market. EU MDR clinical evidence and post-market surveillance obligations slow new model European commercial introductions, making the result steady rather than rapid European endoscope market growth.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national endoscope markets. Brazil's National Cancer Institute colorectal cancer screening programme expanding to include populations over 45 years is driving procedure volume growth at Brazilian public and private hospital endoscopy departments, creating growing GI endoscope procurement demand at Brazilian tertiary hospital gastroenterology programmes. The indirect effects of Iran-US sanctions and Strait of Hormuz freight disruptions have maintained elevated import costs for electronic imaging components and precision optical elements used in premium AI-integrated flexible GI endoscopes entering Brazilian and Mexican hospital supply chains through 2026, suppressing adoption of the highest-specification EVIS X1 and ELUXEO 7000 platforms at cost-sensitive Latin American public hospital programmes that must weigh premium imaging capability against exchange rate and import cost headwinds.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC endoscope markets. Saudi Vision 2030 healthcare investment funding endoscopy department upgrades at tertiary hospital facilities creates demand for Olympus, Fujifilm, and Karl Storz endoscope system procurement at newly commissioned GCC hospital gastroenterology and surgical departments, while South Africa is the most established sub-Saharan market for premium GI endoscope adoption at private hospital group gastroenterology programmes where Mediclinic, Netcare, and Life Healthcare are investing in AI-integrated colonoscopy system upgrades.